全文获取类型
收费全文 | 1228篇 |
免费 | 69篇 |
国内免费 | 5篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 28篇 |
妇产科学 | 4篇 |
基础医学 | 161篇 |
口腔科学 | 12篇 |
临床医学 | 108篇 |
内科学 | 395篇 |
皮肤病学 | 13篇 |
神经病学 | 96篇 |
特种医学 | 52篇 |
外科学 | 158篇 |
综合类 | 6篇 |
预防医学 | 117篇 |
眼科学 | 13篇 |
药学 | 57篇 |
中国医学 | 4篇 |
肿瘤学 | 73篇 |
出版年
2023年 | 3篇 |
2021年 | 20篇 |
2020年 | 11篇 |
2019年 | 28篇 |
2018年 | 39篇 |
2017年 | 18篇 |
2016年 | 19篇 |
2015年 | 22篇 |
2014年 | 41篇 |
2013年 | 53篇 |
2012年 | 72篇 |
2011年 | 74篇 |
2010年 | 42篇 |
2009年 | 42篇 |
2008年 | 63篇 |
2007年 | 59篇 |
2006年 | 65篇 |
2005年 | 73篇 |
2004年 | 66篇 |
2003年 | 50篇 |
2002年 | 66篇 |
2001年 | 44篇 |
2000年 | 47篇 |
1999年 | 50篇 |
1998年 | 10篇 |
1997年 | 10篇 |
1996年 | 3篇 |
1995年 | 11篇 |
1994年 | 7篇 |
1993年 | 4篇 |
1992年 | 25篇 |
1991年 | 15篇 |
1990年 | 20篇 |
1989年 | 15篇 |
1988年 | 8篇 |
1987年 | 14篇 |
1986年 | 9篇 |
1985年 | 10篇 |
1984年 | 8篇 |
1983年 | 3篇 |
1982年 | 4篇 |
1977年 | 9篇 |
1975年 | 5篇 |
1974年 | 8篇 |
1973年 | 4篇 |
1972年 | 10篇 |
1971年 | 4篇 |
1970年 | 3篇 |
1966年 | 2篇 |
1933年 | 2篇 |
排序方式: 共有1302条查询结果,搜索用时 171 毫秒
11.
Antonio Martínez-Aranda Vanessa Hernández Emre Guney Laia Muixí Ruben Foj Núria Baixeras Daniel Cuadras Víctor Moreno Ander Urruticoechea Miguel Gil Baldo Oliva Ferran Moreno Eva González-Suarez Noemí Vidal Xavier Andreu Miquel A. Seguí Rosa Ballester Eva Castella Angels Sierra 《Oncotarget》2015,6(42):44254-44273
Brain metastasis is a devastating problem in patients with breast, lung and melanoma tumors. GRP94 and FN14 are predictive biomarkers over-expressed in primary breast carcinomas that metastasized in brain. To further validate these brain metastasis biomarkers, we performed a multicenter study including 318 patients with breast carcinomas. Among these patients, there were 138 patients with metastasis, of whom 84 had brain metastasis. The likelihood of developing brain metastasis increased by 5.24-fold (95%CI 2.83–9.71) and 2.55- (95%CI 1.52–4.3) in the presence of FN14 and GRP94, respectively. Moreover, FN14 was more sensitive than ErbB2 (38.27 vs. 24.68) with similar specificity (89.43 vs. 89.55) to predict brain metastasis and had identical prognostic value than triple negative patients (p < 0.0001). Furthermore, we used GRP94 and FN14 pathways and GUILD, a network-based disease-gene prioritization program, to pinpoint the genes likely to be therapeutic targets, which resulted in FN14 as the main modulator and thalidomide as the best scored drug. The treatment of mice with brain metastasis improves survival decreasing reactive astrocytes and angiogenesis, and down-regulate FN14 and its ligand TWEAK. In conclusion our results indicate that FN14 and GRP94 are prediction/prognosis markers which open up new possibilities for preventing/treating brain metastasis. 相似文献
12.
13.
Pilar Solves Jaime Sanz Ins Gmez Rosalía de la Puerta Mario Arnao Juan Montoro Jos Luis Piana Carlos Carretero Aitana Balaguer Manuel Guerreiro Rafa Andreu Rebeca Rodríguez Pau Montesinos Isidro Jarque Jos Ignacio Lorenzo Nelly Carpio Miguel ngel Sanz Guillermo Francisco Sanz 《European journal of haematology》2019,103(3):172-177
14.
15.
16.
M.Q. Gorgas Torner F. Pàez Vives J. Camós Ramió E. de Puig Cabrera P. Jolonch Santasusagna E. Homs Peipoch J.A. Schoenenberger Arnaiz C. Codina Jané J. Gómez-Arbonés 《Farmacia hospitalaria》2012,36(4):229-239
ObjectivesTo assess whether an integrated pharmaceutical care programme (IPCP) improves clinical evolution, patient quality of life, and reduces health costs in chronic patients.Material and methodsA parallel, open, and multi-centre clinical trial of an IPCP in patients with heart failure (HF) and/or chronic obstructive pulmonary disease (COPD) in 8 different health areas in Cataluña. The intervened patient was monitored for pharmacotherapeutic evolution by hospital pharmacists, primary care physicians, and community pharmacists. Controls received normal follow-up. All patients were monitored for 12 months, with quality of life tests administered at the beginning and end of follow-up.ResultsWe had the participation of 8 different hospitals, 8 primary care centres, and 109 community pharmacies. 238 patients completed the study, with 2.9% of participants lost during the study period. There were no significant differences in terms of readmissions, visits to the doctors, or to emergency services. We detected 50 different medication-related problems (MRP) in 37 patients, with a statistically significant difference in terms of MRP between the control and treatment groups of patients with HF, and almost significant differences in COPD patients. MRP were moderate-severe in 36% of cases. MRP were avoidable in 94% of cases, and the pharmacist resolved the issue in 90% of cases. There were no differences in terms of patient quality of life or health costs between the start and end of the study.ConclusionsIntegrated pharmaceutical care programs facilitate an improvement in the quality of patient care, but electronic registries are necessary to promote communication between sections of the health care network. 相似文献
17.
18.
Alex Ca?as-Ventura Lucia Márquez Xavier Bessa Josep Maria Dedeu Marc Puigvehí Sílvia Delgado-Aros Ines Ana Ibá?ez Agustin Seoane Luis Barranco Felipe Bory Montserrat Andreu Bego?a González-Suárez 《World journal of gastrointestinal endoscopy》2013,5(11):551-558
AIM: To investigate the clinical impact of capsule endoscopy (CE) after an obscure gastrointestinal bleeding (OGIB) episode, focusing on diagnostic work-up, follow-up and predictive factors of rebleeding.METHODS: Patients who were referred to Hospital del Mar (Barcelona, Spain) between 2007 and 2009 for OGIB who underwent a CE were retrospectively analyzed. Demographic data, current treatment with non-steroid anti-inflammtory drugs or anticoagulant drugs, hemoglobin levels, transfusion requirements, previous diagnostic tests for the bleeding episode, as well as CE findings (significant or non-significant), work-up and patient outcomes were analyzed from electronic charts. Variables were compared by χ2 analysis and Student t test. Risk factors of rebleeding were assessed by Log-rank test, Kaplan-Meier curves and Cox regression model.RESULTS: There were 105 patients [45.7% women, median age of 72 years old (interquartile range 56-79)] and a median follow-up of 326 d (interquartile range 123-641) included in this study. The overall diagnostic yield of CE was 58.1% (55.2% and 63.2%, for patients with occult OGIB and overt OGIB, respectively). In 73 patients (69.5%), OGIB was resolved. Multivariate analysis showed that hemoglobin levels lower than 8 g/dL at diagnosis [hazard ratios (HR) = 2.7, 95%CI: 1.9-6.3], patients aged 70 years and above (HR = 2.1, 95%CI: 1.2-6.1) and significant findings in CE (HR = 2.4, 95%CI: 1.1-5.8) were independent predictors of rebleeding.CONCLUSION: One third of the patients presented with rebleeding after CE; risk factors were hemoglobin levels < 8 g/dL, age ≥ 70 years or the presence of significant lesions. 相似文献
19.
20.
Infections caused by Escherichia coli resistant to norfloxacin in hospitalized cirrhotic patients 总被引:7,自引:0,他引:7
Ortiz J Vila MC Soriano G Miñana J Gana J Mirelis B Novella MT Coll S Sábat M Andreu M Prats G Solá R Guarner C 《Hepatology (Baltimore, Md.)》1999,29(4):1064-1069
Selective intestinal decontamination with norfloxacin is useful to prevent bacterial infections in several groups of cirrhotic patients at high risk of infection. However, the emergence of infections caused by Escherichia coli resistant to quinolones has recently been observed in cirrhotic patients undergoing prophylactic norfloxacin. Our aim is to determine the characteristics of the infections caused by E. coli resistant to norfloxacin in hospitalized cirrhotic patients. One hundred and six infections caused by E. coli in 99 hospitalized cirrhotic patients were analyzed and distributed into two groups: group I (n = 67), infections caused by E. coli sensitive to norfloxacin, and group II (n = 39), infections caused by E. coli resistant to norfloxacin. The clinical and analytical characteristics at diagnosis of the infection were similar in both groups. Previous prophylaxis with norfloxacin was more frequent in group II (15/67, 22.4% vs. 32/39, 82%, P <.0001), as a result of a higher number of patients submitted to continuous long-term prophylaxis in this group, whereas previous short-term prophylaxis was similar in both groups. Infections were more frequently nosocomial-acquired in group II than in group I (17/67, 25.3% vs. 20/39, 51.2%, P =.01). The type of infections was similar in both groups: urinary tract infections 38 in group I and 24 in group II, spontaneous bacterial peritonitis 8 and 2, spontaneous bacteremia 4 and 4, and bacterascites 1 and 0, respectively (pNS). Mortality during hospitalization was similar in the two groups (4/67, 5.9% vs. 5/39, 12.8%, pNS). None of the E. coli resistant to norfloxacin were also resistant to cefotaxime and only one of them was resistant to amoxicillin-clavulanic acid. Prophylaxis with norfloxacin, usually continuous long-term prophylaxis, favors the development of infections caused by norfloxacin-resistant E. coli. Long-term antibiotic prophylaxis should therefore be restricted to highly selected groups of cirrhotic patients at high-risk of infection. Infections caused by E. coli resistant to norfloxacin show a severity similar to those caused by sensitive E. coli. No significant associated resistance between norfloxacin and the antibiotics most frequently used in the treatment of bacterial infections in cirrhotic patients has been observed. 相似文献